1 Oct 2026, 17:19
Meetings & Governance—
NTINEUROTECH INTERNATIONAL LIMITED
Announcement history available from 1 August 2025
Fromto
21 Sept 2026, 08:51
Company UpdateMS
8 Sept 2026, 19:24
Director Interests—
8 Sept 2026, 16:46
Securities Administration—
8 Sept 2026, 09:49
Company Administration—
8 Sept 2026, 09:48
Director Interests—
26 Aug 2026, 17:23
Company Administration—
26 Aug 2026, 17:19
Financial ResultsMS
17 Aug 2026, 09:33
Company Administration—
13 Aug 2026, 13:39
Substantial Holders—
11 Aug 2026, 18:01
Securities Administration—
11 Aug 2026, 17:58
Securities Administration—
4 Aug 2026, 09:27
Securities Administration—
4 Aug 2026, 09:27
Securities Administration—
4 Aug 2026, 09:26
Capital RaisingMS
31 July 2026, 10:59
Quarterly ReportsMS
31 July 2026, 09:22
Trading Halt / SuspensionMS
30 July 2026, 09:00
Company Update—
21 July 2026, 16:43
Securities Administration—
21 July 2026, 16:37
Securities Administration—
15 July 2026, 12:11
Periodic ReportsMS
14 July 2026, 08:50
Company UpdateMS
13 July 2026, 19:16
Securities Administration—
13 July 2026, 09:32
Securities Administration—
2 July 2026, 09:35
Company UpdateMS
29 June 2026, 16:39
Securities Administration—
29 Apr 2026, 09:42
Quarterly ReportsMS
28 Apr 2026, 15:20
Director Interests—
28 Apr 2026, 15:18
Securities Administration—
23 Apr 2026, 18:40
Substantial Holders—
13 Apr 2026, 09:19
Presentations—
31 Mar 2026, 18:17
Director Interests—
30 Mar 2026, 18:44
Securities Administration—
30 Mar 2026, 18:37
Securities Administration—
23 Mar 2026, 09:28
Presentations—
18 Mar 2026, 09:33
Presentations—
17 Mar 2026, 09:32
Company UpdateMS
12 Mar 2026, 14:10
Meetings & Governance—
26 Feb 2026, 18:15
Financial ResultsMS
23 Feb 2026, 09:45
Company UpdateMS
18 Feb 2026, 09:38
Company Update—
10 Feb 2026, 16:10
Meetings & Governance—
2 Feb 2026, 09:36
Company UpdateMS
30 Jan 2026, 08:56
Quarterly ReportsMS
15 Jan 2026, 09:35
Company Update—
24 Dec 2025, 13:32
Securities Administration—
24 Dec 2025, 13:31
Securities Administration—
23 Dec 2025, 12:03
Director Interests—
23 Dec 2025, 12:01
Securities Administration—
17 Dec 2025, 10:02
Securities Administration—
| Date / Time | Heading | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 1 Oct 2026, 17:19 | Notice of Annual General Meeting/Proxy Form | Meetings & Governance | — | 08001, 08004 | |
| 21 Sept 2026, 08:51 | NTI Doses First Patient in Phase 3 Beyond Harmony ASD Study | Company Update | MS | 11001 | |
| 8 Sept 2026, 19:24 | Initial Director's Interest Notice | Director Interests | — | 02008 | |
| 8 Sept 2026, 16:46 | Notification of cessation of securities - NTI | Securities Administration | — | 06027 | |
| 8 Sept 2026, 09:49 | Board and Management Changes | Company Administration | — | 12001, 12017 | |
| 8 Sept 2026, 09:48 | Final Director's Interest Notice | Director Interests | — | 02010 | |
| 26 Aug 2026, 17:23 | Appendix 4G and Corporate Governance Statement | Company Administration | — | 03024, 03025 | |
| 26 Aug 2026, 17:19 | Appendix 4E & Annual Report to shareholders | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020 | |
| 17 Aug 2026, 09:33 | Appointment of Executive Chairman | Company Administration | — | 12017 | |
| 13 Aug 2026, 13:39 | Becoming a substantial holder | Substantial Holders | — | 02001 | |
| 11 Aug 2026, 18:01 | Secondary Trading Notice | Securities Administration | — | 06018 | |
| 11 Aug 2026, 17:58 | Application for quotation of securities - NTI | Securities Administration | — | 06020 | |
| 4 Aug 2026, 09:27 | Proposed issue of securities - NTI | Securities Administration | — | 06013 | |
| 4 Aug 2026, 09:27 | Proposed issue of securities - NTI | Securities Administration | — | 06013 | |
| 4 Aug 2026, 09:26 | Receipt of Binding Commitments for $4.5m Placement | Capital Raising | MS | 06003, 09014 | |
| 31 July 2026, 10:59 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19004, 19009 | |
| 31 July 2026, 09:22 | Trading Halt | Trading Halt / Suspension | MS | 09007 | |
| 30 July 2026, 09:00 | NTI164 Phase II/III Autism Data Accepted for Publication | Company Update | — | 11001 | |
| 21 July 2026, 16:43 | Secondary Trading Notice | Securities Administration | — | 06018 | |
| 21 July 2026, 16:37 | Application for quotation of securities - NTI | Securities Administration | — | 06020 | |
| 15 July 2026, 12:11 | Neurotech secures $3.15 million R&D tax incentive loan | Periodic Reports | MS | 03014, 12008 | |
| 14 July 2026, 08:50 | US FDA clears IND for NTI164 | Company Update | MS | 11001 | |
| 13 July 2026, 19:16 | Notification regarding unquoted securities - NTI | Securities Administration | — | 06021 | |
| 13 July 2026, 09:32 | Proposed issue of securities - NTI | Securities Administration | — | 06013 | |
| 2 July 2026, 09:35 | NTI secures Notices of Allowance for US patent applications | Company Update | MS | 11001 | |
| 29 June 2026, 16:39 | Notification of cessation of securities - NTI | Securities Administration | — | 06027 | |
| 29 Apr 2026, 09:42 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19003, 19008 | |
| 28 Apr 2026, 15:20 | Change of Director's Interest Notice | Director Interests | — | 02009 | |
| 28 Apr 2026, 15:18 | Notification of cessation of securities - NTI | Securities Administration | — | 06027 | |
| 23 Apr 2026, 18:40 | Ceasing to be a substantial holder | Substantial Holders | — | 02003 | |
| 13 Apr 2026, 09:19 | Neurotech to present at Ignite Investment Summit Hong Kong | Presentations | — | 03026 | |
| 31 Mar 2026, 18:17 | Change of Director's Interest Notice x 4 | Director Interests | — | 02009 | |
| 30 Mar 2026, 18:44 | Secondary Trading Notice | Securities Administration | — | 06018 | |
| 30 Mar 2026, 18:37 | Application for quotation of securities - NTI | Securities Administration | — | 06020 | |
| 23 Mar 2026, 09:28 | Neurotech to present at NWR Virtual Healthcare Conference | Presentations | — | 14014 | |
| 18 Mar 2026, 09:33 | Corporate Presentation | Presentations | — | 03026 | |
| 17 Mar 2026, 09:32 | NTI initiates First Clinical Site for Phase 3 ASD Trial | Company Update | MS | 11001 | |
| 12 Mar 2026, 14:10 | Results of General Meeting | Meetings & Governance | — | 08003 | |
| 26 Feb 2026, 18:15 | Appendix 4D & Half Year Report | Financial Results | MS | 03004, 03009, 03010, 03015, 03019 | |
| 23 Feb 2026, 09:45 | Positive 90-day GLP toxicology study results in non-rodents | Company Update | MS | 11001 | |
| 18 Feb 2026, 09:38 | NTI Collaborates with University of Sydney in Rett program | Company Update | — | 11001 | |
| 10 Feb 2026, 16:10 | Notice of General Meeting/Proxy Form | Meetings & Governance | — | 08004, 08007, 16002 | |
| 2 Feb 2026, 09:36 | Approval received for NTI164 Phase 3 Clinical Study in ASD | Company Update | MS | 11001 | |
| 30 Jan 2026, 08:56 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19002, 19007 | |
| 15 Jan 2026, 09:35 | PANS Data Published in Leading Scientific Journal | Company Update | — | 11001 | |
| 24 Dec 2025, 13:32 | Secondary Trading Notice | Securities Administration | — | 06018 | |
| 24 Dec 2025, 13:31 | Application for quotation of securities - NTI | Securities Administration | — | 06020 | |
| 23 Dec 2025, 12:03 | Change of Director's Interest Notice | Director Interests | — | 02009 | |
| 23 Dec 2025, 12:01 | Notification of cessation of securities - NTI | Securities Administration | — | 06027 | |
| 17 Dec 2025, 10:02 | Proposed issue of securities - NTI | Securities Administration | — | 06013 |
1–50 of 64
1 / 2